
Opinion|Videos|June 4, 2024
Reflex Testing for Patients with Suspected Lung Cancer
Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.
Advertisement
Episodes in this series

- Please discuss the rationale for conducting liquid-based testing at the time of diagnostic biopsy in patients with suspected advanced NSCLC vs a reflex testing approach. (
Thompson JC, et al. JTO Clin Res Rep, 2022 )
- What do prospective data demonstrate?
- Please comment on the goal of having test results available upon the first patient interaction.
- Please discuss data surrounding the impact of concurrent liquid and tissue-based testing on the quality of care in advanced NSCLC. (
Maity, et al. JCO Oncology Practice, 2023 )- What impact does concurrent testing have on time to diagnosis, the need for repeat tissue biopsy, detection of actionable biomarkers?
- What are some limitations associated with tissue-based testing?
- What do data demonstrate regarding the availability of molecular testing results and overall survival of patients with advanced NSCLC? (
Aggarwal, et al. JCO Prec Oncol, 2023 )
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC
5


